NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 203 filers reported holding NEVRO CORP in Q2 2017. The put-call ratio across all filers is 1.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $472,000 | +3.7% | 3,947 | -13.2% | 0.13% | -43.1% |
Q1 2020 | $455,000 | +175.8% | 4,547 | +224.8% | 0.23% | +625.0% |
Q4 2019 | $165,000 | +768.4% | 1,400 | +366.7% | 0.03% | +540.0% |
Q2 2019 | $19,000 | +35.7% | 300 | -15.7% | 0.01% | 0.0% |
Q4 2018 | $14,000 | -93.9% | 356 | -91.1% | 0.01% | -88.4% |
Q3 2018 | $230,000 | +2455.6% | 4,000 | +3900.0% | 0.04% | +2050.0% |
Q1 2018 | $9,000 | -67.9% | 100 | -75.0% | 0.00% | -66.7% |
Q4 2017 | $28,000 | -74.3% | 400 | -66.7% | 0.01% | -75.0% |
Q3 2017 | $109,000 | -79.5% | 1,200 | -83.2% | 0.02% | -69.2% |
Q2 2017 | $532,000 | -43.2% | 7,145 | -28.6% | 0.08% | -27.8% |
Q1 2017 | $937,000 | +92.4% | 10,000 | +49.2% | 0.11% | +77.0% |
Q4 2016 | $487,000 | -8.5% | 6,701 | +31.4% | 0.06% | -11.6% |
Q3 2016 | $532,000 | -18.9% | 5,100 | -42.7% | 0.07% | -24.2% |
Q2 2016 | $656,000 | – | 8,900 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 622,615 | $38,920,000 | 8.04% |
Tamarack Advisers, LP | 160,000 | $10,002,000 | 3.97% |
Birch Run Capital Advisors, LP | 187,425 | $11,716,000 | 3.72% |
Prosight Management, LP | 128,765 | $8,049,000 | 3.52% |
Ratan Capital Management LP | 38,653 | $2,416,000 | 3.44% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 579,463 | $36,222,000 | 1.39% |
Spark Investment Management LLC | 403,400 | $25,216,000 | 1.17% |
Sivik Global Healthcare LLC | 50,000 | $3,126,000 | 1.15% |
ArrowMark Colorado Holdings LLC | 1,882,009 | $117,644,000 | 1.11% |
PFM Health Sciences, LP | 721,229 | $45,084,000 | 1.00% |